{"doi":"10.1097/ccm.0b013e31818f222b","title":"Management of severe hyperkalemia","abstract":null,"journal":"Critical Care Medicine","year":2008,"id":673788,"datarank":0.839206706940276,"base_score":5.594711379601839,"endowment":5.594711379601839,"self_citation_contribution":0.839206706940276,"citation_network_contribution":0.0,"self_endowment_contribution":0.839206706940276,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":268,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":10,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1760426,"name":"Lawrence S. Weisberg","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Management of severe hyperkalemia","abstract":"BACKGROUND AND OBJECTIVES: Hyperkalemia is one of the few potentially lethal electrolyte disturbances. Prompt recognition and expeditious treatment of severe hyperkalemia are expected to save lives. This review is intended to provide intensivists and other interested clinicians with an understanding of the pathophysiology that underlies hyperkalemia, and a rational approach to its management. METHODS: This article reviews and analyzes literature relevant to the pathophysiology and management of severe hyperkalemia. Methods include search of MEDLINE, and bibliographic search of current textbooks and journal articles. RESULTS AND CONCLUSIONS: A more complete understanding of potassium homeostasis in recent years has led to new approaches to the management of severe hyperkalemia. The physiologically based sequential approach still applies. The efficacy, pitfalls, and risks of the agents available for use at each step in the sequence are critically reviewed. Rational use of the available tools will allow clinicians to successfully treat severe hyperkalemia.","is_dataset_classified":null,"base_score":5.594711379601839,"endowment":5.594711379601839,"datacite_reuse_total":10,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"18936701","pmcid":null,"openalex_id":"https://openalex.org/W2052349502","authors":[],"funders":[],"total_grants":0,"fwci":7.5929,"citation_percentile":0.975726,"influential_citations":11,"citation_trend":[{"year":2012,"count":20},{"year":2013,"count":12},{"year":2014,"count":14},{"year":2015,"count":21},{"year":2016,"count":22},{"year":2017,"count":24},{"year":2018,"count":13},{"year":2019,"count":20},{"year":2020,"count":18},{"year":2021,"count":15},{"year":2022,"count":9},{"year":2023,"count":11},{"year":2024,"count":20},{"year":2025,"count":12},{"year":2026,"count":4}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.ovid.com/10.1097/CCM.0b013e31818f222b","host_type":"publisher"},{"url":"https://doi.org/10.1097/ccm.0b013e31818f222b","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/18936701","host_type":"repository"}],"fields_of_study":["Potassium and Related Disorders","Clinical Laboratory Practices and Quality Control","Magnesium in Health and Disease","Medicine","Humans","Hyperkalemia","Potassium"],"mesh_terms":["Humans","Hyperkalemia","Potassium"],"keywords":["Hyperkalemia","Medicine","Intensive care medicine","MEDLINE","Review article","Internal medicine","Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.12781453.v1","title":"Additional file 1 of The burden of hyperkalemia in Germany – a real world evidence study assessing the treatment and costs of hyperkalemia","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.12781453","title":"Additional file 1 of The burden of hyperkalemia in Germany – a real world evidence study assessing the treatment and costs of hyperkalemia","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573761.v1","title":"Additional file 1 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573761","title":"Additional file 1 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573764.v1","title":"Additional file 2 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573764","title":"Additional file 2 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573767.v1","title":"Additional file 3 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573767","title":"Additional file 3 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573770.v1","title":"Additional file 4 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26573770","title":"Additional file 4 of A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T14:30:00.175507Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}